Focus on pemphigus treatment publications: A bibliometric and visual analysis (1992-2022).

Pemphigus is a chronic recurrent disease in dermatology. Although it is not very common, its treatment has been an increasing concern in recent years because it is difficult and long-lasting. At present, there are many papers on pemphigus treatment, and to better understand the research trends and research frontiers of pemphigus treatment, it is necessary to conduct a comprehensive systematic review and analysis. We combined bibliometric and visualization methods to analyze 1365 papers published in the Web of Science database from 1992 to 2022, including basic information about countries, institutions and authors, to gain a general understanding of the treatment of pemphigus. Among them, the United States is the country with the most output, Iran's Tehran University of Medical Sciences is the institution with the most published works, and Ahmed, A. Razzaque of Tufts University is the most influential scholar. In addition, we also learned about the research hotspots and frontiers of pemphigus treatment through a series of analyses on the frequency, clustering, keywords bursts and cited literature, and we briefly reviewed the highly cited literature. We found that the current research focuses in the study of pemphigus treatment are the types, pathogenesis, and treatment of pemphigus, including glucocorticoids, immunosuppressants and many other major treatment methods. Hailey-Hailey disease, genetic susceptibility, and traditional Chinese medicine are potential research hotspots. Rituximab is a research frontier. In conclusion, we hope to provide new research ideas for promoting the development of pemphigus treatment.

Propagation properties of elegant modified Bessel Gaussian beams.

A kind of optical beam with a radially parabolic propagating manner and intensity decay inversely proportional to propagating distance in the far field is investigated. The initial complex amplitudes of this kind of beam have the form of a Gaussian function multiplied by a m/2-order modified Bessel function and a helical phase factor with topological charge m. The arguments for Bessel and Gauss parts in the propagating solutions of these beams are complex and symmetric as elegant Laguerre and Hermite Gaussian beams. As a result, the beams can be referred to as elegant modified Bessel Gauss (EMBG) beams. Similar to non-diffractive beams such as Bessel and Airy beams, the EMBG beams also carry infinite power due to a transversely slowly decaying tail of complex amplitude. The EMBG beams demonstrate intermediate propagating properties between non-diffractive and finite-power beams. Unlike non-diffractive beams that never spread their power and finite-power beams that always diverge in a linear manner and spread their power by inversely square law in the far field, the EMBG beams demonstrate a far-field parabolic propagating manner and decay their power by inversely linear law. In addition, the EMBG beams have total Gouy phase, which is only half of that of elegant Laguerre Gauss beams with the same topological charge, and have far-field intensity distributions regardless of the beam waist radius in the initial plane. The propagating and focusing properties of EMBG beams represent an intermediate status between the non-diffractive and finite-power beams.

Geometric phase-encoded stimuli-responsive cholesteric liquid crystals for visualizing real-time remote monitoring: humidity sensing as a proof of concept.

Liquid crystals are a vital component of modern photonics, and recent studies have demonstrated the exceptional sensing properties of stimuli-responsive cholesteric liquid crystals. However, existing cholesteric liquid crystal-based sensors often rely on the naked eye perceptibility of structural color or the measurement of wavelength changes by spectrometric tools, which limits their practical applications. Therefore, developing a platform that produces recognizable sensing signals is critical. In this study, we present a visual sensing platform based on geometric phase encoding of stimuli-responsive cholesteric liquid crystal polymers that generates real-time visual patterns, rather than frequency changes. To demonstrate this platform's effectiveness, we used a humidity-responsive cholesteric liquid crystal polymer film encoded with a q-plate pattern, which revealed that humidity causes a shape change in the vortex beam reflected from the encoded cholesteric liquid crystal polymers. Moreover, we developed a prototype platform towards remote humidity monitoring benefiting from the high directionality and long-range transmission properties of laser beams carrying orbital angular momentum. Our approach provides a novel sensing platform for cholesteric liquid crystals-based sensors that offers promising practical applications. The ability to generate recognizable sensing signals through visual patterns offers a new level of practicality in the sensing field with stimuli-responsive cholesteric liquid crystals. This platform might have significant implications for a broad readership and will be of interest to researchers working in the field of photonics and sensing technology.

Propagating analysis of Airy beams via complex phase space and ray method.

A complex phase space and ray method is proposed to present intuitive interpretation of unique intensity profiles, parabolic accelerating trajectories, and distinctive phase shifts of Airy beam and its exponentially decaying version (i.e., finite-energy Airy beam). In the complex phase space, finite-energy Airy beam manifests itself as a complex parabolic phase space curve (PSC) which represents a cluster of light rays with complex wave vectors. The complex ray cluster converges to a complex parabolic caustic curve in complex coordinate space. For infinite-energy Airy beam, phase space, PSC, light ray and caustic curve change to real values. In the paraxial condition, Airy beams can maintain parabolic form of PSC and keep constant ray density, which guarantees the non-diffraction property of Airy beam and approximate non-diffraction property of finite-energy Airy beam. From the evolution of vertexes of parabolic PSC along a parabolic trajectory in phase space, one can also give the parabolic caustic curve for Airy beam and the complex parabolic caustic curve for exponentially decaying Airy beam. Further, the special phase and decay factors in the propagating solution of complex amplitude of Airy beams can be directly derived from the phase shifts of light ray cluster along transverse and longitudinal directions. The proposed phase space and ray method can present intuitive comprehension to distinctive propagating characteristics of Airy beams including intensity and phase, without resort to solving wave equation or diffracting integral formula.

Targeting the Akt/PI3K/mTOR signaling pathway for complete eradication of keloid disease by sunitinib.

Keloid disease is a nodular lesion, tumor-like but not cancerous, and characterized of excessive proliferation of fibroblasts and deposition of extracellular matrix (ECM) components. This condition often causes itching, pain and cosmetic disfigurement, significantly reducing patient quality of life. To date, no universally effective therapies are available, possibly due to inadequate understanding of keloid pathogenesis. As an oral small-molecule inhibitor of certain tyrosine kinase receptors, sunitinib has shown significant therapeutic effects in renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST). However, it has never been tested if keloid therapy can be effective for the management of keloids. This study thus aims to explore the potential of sunitinib for keloid treatment. Keloid-derived fibroblasts (KFs) were successfully isolated and demonstrated proliferative advantage to normal skin-derived fibroblasts (NFs). Additionally, sunitinib showed specific cytotoxicity and inhibition of invasion, and induced cell cycle arrest and significant apoptosis in KFs. These effects were accompanied by complete suppression of ECM component expression, including collagen types 1 and 3, upregulation of autophagy-associated LC3B and significant suppression of the Akt/PI3K/mTOR pathway. Moreover, a keloid explant culture model was successfully established and used to test the therapeutic efficacy of sunitinib on keloid formation in nude mice. Sunitinib was found to induce complete regression of keloid explant fragments in nude mice, showing significantly higher therapeutic efficacy than the most commonly used intralesional drug triamcinolone acetonide (TAC). These data suggest that sunitinib effectively inhibits keloid development through suppression of the Akt/PI3K/mTOR pathway and thus can be potentially developed as a monotherapy or combination therapy for the effective treatment of keloid disease.

EV-T synergizes with AZD5582 to overcome TRAIL resistance through concomitant suppression of cFLIP, MCL-1, and IAPs in hepatocarcinoma.

Hepatocellular carcinoma (HCC) is an aggressive malignancy, and its effective treatment has been hampered by drug resistance. Extracellular vesicle (EV) delivery of TNF-related apoptosis-inducing ligand (TRAIL) (EV-T) was demonstrated to be superior to recombinant TRAIL (rTRAIL) for cancer treatment previously. And AZD5582, a potent antagonist of inhibitors of apoptosis proteins (IAPs) can potentiate apoptosis-based cancer therapies. However, the combination of EV-T and AZD5582 has never been examined for their possible apoptosis inducing synergism in cancers. In this study, we proposed and tested the combination of EV-T and AZD5582 as a potential novel therapy for effective treatment of HCC. Two HCC lines Huh7 and HepG2 that are both resistant to rTRAIL were examined. The results confirmed that AZD5582 and EV-T are synergistic for apoptosis induction in some cancer lines including Huh7 and HepG2 while sparing normal cells. More importantly, this study revealed that TRAIL sensitization by AZD5582 is mediated through the concomitant suppression of anti-apoptotic factors including cFLIP, MCL-1, and IAPs (XIAP, Survivin and cIAP-1). Particularly the downregulation of cFLIP and IAP's appeared to be essential and necessary for the synergism between AZD5582 and TRAIL. In vivo, we first time demonstrated that the combined therapy with low doses of AZD5582 and EV-Ts triggered drastically enhanced apoptosis leading to the complete eradication of Huh7 tumor development without any apparent adverse side effects examined. We thus have unraveled the important molecular mechanism underlying TRAIL sensitization by AZD5582, rationalizing the next development of a combination therapy with AZD5582 and EV-T for HCC treatment. KEY MESSAGES: It confirmed the TRAIL sensitization by AZD5582, a potent antagonist of IAPs in hepatocarcinoma. It revealed that the sensitization is via the concomitant suppression of antiapoptotic factors including cFLIP, MCL-1, and IAPs. The downregulation of cFLIP and IAPs like Survivin appeared to be essential and necessary for the synergism between AZD5582 and nanosomal TRAIL. In vivo the combined therapy with AZD5582 and nanosomal TRAIL led to complete eradication of hepatocarcinoma tumors. This study has rationalized the next development of a combination therapy with AZD5582 and nanosomal TRAIL for cancer treatment.

Extracellular vesicle-mediated co-delivery of TRAIL and dinaciclib for targeted therapy of resistant tumors.

Extracellular vesicle (EV) delivery of TNF-related apoptosis-inducing ligand (TRAIL) (EV-T) has been shown to be highly efficient for cancer treatment when combined with the potent cyclin-dependent kinase (CDK) inhibitor dinaciclib (SCH727965, Dina). However, only topical administration was previously tested for cancer treatment, leaving unknown the efficacy of systemic therapy by EV-T and Dina. In this study we hypothesize that the systemic application of EV-T and Dina can be performed through EV-mediated co-delivery of TRAIL and Dina. Dina was first post-loaded into EV-Ts by sonication to prepare EV-mediated co-delivery of TRAIL and Dina, designated Dina@EV-T. Then Dina@EV-Ts were shown to be stable, readily endocytosed into cancer cells, and highly effective at inducing intensive apoptosis in resistant cancer lines but not in normal cells. Moreover, systemically infused Dina@EV-Ts showed evident tumor tropism suggesting their good potential for tumour-targeted delivery of therapeutics. Importantly, the systemic therapy with Dina@EV-Ts showed the best efficacy in vivo when compared with other treatments. The augmented therapeutic efficacy appeared to be associated with the concomitant suppression of prosurvival CDK1 and anti-apoptotic proteins including CDK9, cFLIP, MCL-1, BCL-2 and Survivin by Dina@EV-T treatment. Additionally, there were no adverse side effects observed for the systemic Dina@EV-T therapy. In conclusion, our data suggest that the co-delivery of TRAIL and Dina by EVs potentially constitutes a novel tumour-targeted therapy, which is highly effective and safe for the treatment of refractory tumors.

Sensitizing TRAIL response via differential modulation of anti- and pro-apoptotic factors by AZD5582 combined with ER nanosomal TRAIL in neuroblastoma.

Neuroblastoma is a metastatic brain tumor particularly common in children. The cure rate is below 50% for patients of high-risk condition. Novel therapeutic agents and approaches are needed to improve the cure rate. Tumor necrosis factor-related and apoptosis-inducing ligand (TRAIL) is a promising proapoptotic factor that rapidly induces apoptosis preferentially in transformed and cancerous cells. Unfortunately, the common TRAIL resistance in cancers has hampered the clinical application of the ligand. Previously we prepared a novel TRAIL-armed ER derived nanosomal agent (ERN-T) that overcomes TRAIL resistance in some cancer lines when combined with a synthetic antagonist of inhibitors of apoptosis proteins (IAPs), AZD5582. However, how AZD5582 sensitizes cancer cells to ERN-T remains not well understood. In this study we continued to test the therapeutic efficacy of the combinatory therapy of ERN-T and AZD5582 on neuroblastoma, aiming to reveal the molecular mechanism underlying the synergism between AZD5582 and ERN-T. The obtained data revealed that ERN-Ts overcame TRAIL resistance and showed significant cytotoxicity on the resistant neuroblastoma line SH-SH5Y when combined with AZD5582 whilst sparing normal cells. The combination of low doses of ERN-Ts and AZD5582 induced intensive apoptosis in SH-SY5Y but not in normal skin fibroblasts (NSFs). Importantly we discovered that TRAIL sensitization in SH-SY5Y was associated with the concomitant downregulation of antiapoptotic factors cFLIP, MCL-1 and IAPs and upregulation of proapoptotic protein BAX and the death receptor 5 (DR5) by the cotreatment of ERN-T and AZD5582. In vivo study demonstrated that the combination of ERN-T and AZD5582 constituted a highly effective and safe therapy for subcutaneous SH-SY5Y xenograft neuroblastoma in nude mice. In conclusion, we identified that the concomitant regulation of both antiapoptotic and proapoptotic factors and DR5 is an essential molecular mechanism for overcoming TRAIL resistance in SH-SY5Y and the combination of ERN-T and AZD5582 potentially constitutes a novel therapeutic strategy, which is highly effective and safe for neuroblastoma.

TRAIL-Armed ER Nanosomes Induce Drastically Enhanced Apoptosis in Resistant Tumor in Combination with the Antagonist of IAPs (AZD5582).

Although mesenchymal stem cells (MSCs) can be engineered to deliver the TNF-related apoptosis-inducing ligand (TRAIL) as an effective anticancer therapy, the clinical application is hampered by the costly manufacturing of therapeutic MSCs. Therefore, it is needed to find an alternative cell-free therapy. In this study, TRAIL-armed endoplasmic reticulum (ER)-derived nanosomes (ERN-T) are successfully prepared with an average size of 70.6 nm in diameter from TRAIL transduced MSCs. It is demonstrated that the ERN-T is significantly more efficient for cancer cell killing than the soluble recombinant TRAIL (rTRAIL). AZD5582 is an antagonist of the inhibitors of apoptosis proteins (IAPs), and its combination with ERN-T induces strikingly enhanced apoptosis in cancerous but not normal cells. AZD5582 sensitizes resistant cancer cells to TRAIL through concomitant downregulation of IAP members like XIAP and the Bcl2 family member Mcl-1. Intravenously infused ERN-Ts accumulate in tumors for over 48 h indicating good tumor tropism and retention. The combination of ERN-T and AZD5582 drastically promotes therapeutic efficacy comparing with the cotreatment by rTRAIL and AZD5582 in a subcutaneous MDA-MB-231 xenograft tumor model. The data thus demonstrate that ERN-T can be a novel cell-free alternative to TRAIL-expressing MSC-based anticancer therapy and its efficacy can be drastically enhanced through combination with AZD5582.

Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib.

Tumour necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) is a promising anti-cancer agent that rapidly induces apoptosis in cancer cells. Unfortunately, the clinical application of recombinant TRAIL (rTRAIL) has been hampered by its common cancer resistance. Naturally TRAIL is delivered as a membrane-bound form by extracellular vesicles (EV-T) and is highly efficient for apoptosis induction. SCH727965 (dinaciclib), a potent cyclin-dependent kinase (CDK) inhibitor, was shown to synergize with other drugs to get better efficacy. However, it has never been investigated if dinaciclib coordinates with EV-T to enhance therapeutic results. This study explores the potential of combination therapy with EV-T and dinaciclib for cancer treatment. EV-T was successfully derived from human TRAIL transduced cells and shown to partially overcome resistance of A549 cells. Dinaciclib was shown to drastically enhance EV-T killing effects on cancer lines that express good levels of death receptor (DR) 5, which are associated with suppression of CDK1, CDK9 and anti-apoptotic proteins. Combination therapy with low doses of EV-T and dinaciclib induced strikingly enhanced apoptosis and led to complete regression in A549 tumors without any adverse side effects observed in a subcutaneous xenograft model. Tumor infiltration of mass NK cells and macrophages was also observed. These observations thus indicate that the combination of EV-T with dinaciclib is a potential novel therapy for highly effective and safe cancer treatment.

Prolactin and Thyroid Stimulating Hormone (TSH) Levels and Sexual Dysfunction in Patients with Schizophrenia Treated with Conventional Antipsychotic Medication: A Cross-Sectional Study.

BACKGROUND This study aimed to investigate the relationship between serum profiles of prolactin and thyroid stimulating hormone (TSH) and sexual dysfunction in patients with schizophrenia treated with conventional antipsychotic medication. MATERIAL AND METHODS A hospital-based cross-sectional study included 118 patients, age range 18-57 years (55 men, 63 women), with a confirmed diagnosis of schizophrenia. All patients were stable after antipsychotic treatment. Serum levels of hormones, including prolactin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), progesterone, testosterone, thyroid-stimulating hormone (TSH), triiodothyronine (T3), thyroxine (T4), free triiodothyronine (FT3) and free thyroxine (FT4), were detected in venous blood. The Positive and Negative Syndrome Scale (PANSS) score was used to measure symptom severity of patients with schizophrenia. The Mandarin Chinese version of the Arizona Sexual Experience Scale (ASEX), a 5-item scale, was used to measure sexual function. RESULTS There were 66 patients (55.9%) who had hyperprolactinemia, the prevalence of hyperprolactinemia was markedly higher in the sexual dysfunction group than the non-sexual dysfunction group (91.8% vs. 17.5%) (P<0.001). Mean prolactin levels were significantly increased in patients with sexual dysfunction compared with the patients without sexual dysfunction (P<0.001), with a higher incidence in female patients. Subclinical hypothyroidism and hyperprolactinemia were found to be independently associated with sexual dysfunction, and an increased PANSS negative score was an independent risk factor for the development of sexual dysfunction. CONCLUSIONS The incidence of sexual dysfunction was significantly increased in patients with schizophrenia. Hyperprolactinemia and subclinical hypothyroidism were associated with sexual dysfunction, especially in female patients.

Hyperbolic accelerating beams and their relation with Hermite-Gaussian beams.

We derive the initial distributions of phase and complex amplitude of accelerating beams with arbitrary predesigned hyperbolic trajectories using the caustic-design method and explore the relation between these beams and Hermite-Gaussian beams. The results show the hyperbolic accelerating beams are a larger class of beams than Hermite-Gaussian beams. When the bending parameter is an integer, the hyperbolic accelerating beams have a similar initial complex amplitude distribution and almost the same propagating characteristics as Hermite-Gaussian beams. Through the analysis of the ray-based method, we also derive an approximate expression for the initial complex amplitude of Hermite-Gaussian beams after introducing an amplitude distribution function. Although the proposed approximate expressions of complex amplitude are more complex than the usually used Hermite-Gaussian function, they explicitly indicate the information on local amplitude, wave vector, and internal ray structure (including caustics) of these beams and thus provide us clearer geometrical insights into these beams.

Orbital angular momentum and paraxial propagation characteristics of non-coaxial Laguerre-Gaussian beams.

The orbital angular momentum (OAM) and paraxial propagation characteristics of non-coaxial Laguerre-Gaussian (LG) beams are discussed. In the initial plane, the amplitudes of non-coaxial LG modes are the product of a Laguerre polynomial, a vortex phase factor, and a non-coaxial Gaussian window function. Because of displacement between the centroid and vortex center of the beams, the non-coaxial LG beams demonstrate a non-zero extrinsic OAM, which causes the propagation of beam centroid to have a small tilt angle relative to the z axis. Through separating the extrinsic OAM from the total OAM carried by the non-coaxial LG beams, the tilt angle and trajectory of the beam centroid are derived. Furthermore, the paraxial propagating characteristics of these beams are also discussed analytically. The results show the vortex center initially at origin demonstrates a linear lateral shift with propagation and the peak of transverse intensity has a trajectory of a straight line, although the intensity profile rotates itself with propagation.

Noncoaxial Bessel-Gauss beams.

We proposed a new family of noncoaxial Gauss-truncated Bessel beams through multiplying conventional symmetrical Bessel beams by a noncoaxial Gauss function. These beams can also be regarded as the exponential-truncated version of Bessel-Gauss beams since they can be transformed into the product of Bessel-Gauss beams and an exponential window function along a certain Cartesian axis. The closed-form solutions of the angular spectra and paraxial propagation of these beams were derived. These beams have asymmetrical intensity distributions and carry the same orbit angular momentum per photon as the corresponding Bessel-Gauss beams. While propagating along the z axis, the mth (m≠0) noncoaxial Bessel-Gauss beams rotate their intensity distributions and the mth-order vortex at the beam center has a transverse shift along the direction perpendicular to the offset axis. Depending on the product of the transverse scalar factor of the Bessel beams and the offset between the Gaussian window function and the center of the Bessel beams, the noncoaxial Bessel-Gauss beams can produce unit vortices with opposite signs in pairs during propagation.

Accelerating propagation properties of misplaced Hermite-Gaussian beams.

A new family of finite-energy accelerating beams was constructed through misplacing the Hermite polynomial and Gaussian window function. The closed-form solution of k-space spectra and paraxial propagation of these beams are derived from the Fourier transform and the scalar angle spectra integral. These beams have similar propagation properties to finite Airy beams and parabolic beams, but the accelerating trajectory is hyperbola rather than parabola. The beam family can be experimentally generated by exponentially truncating the high-order Hermite-Gaussian beams in the spatial domain.

Fast and noninterpolating method for subpixel displacement analysis of digital speckle images using phase shifts of spatial frequency spectra.

A fast noninterpolation method for calculating displacement of digital speckle images with subpixel precision was introduced. In this method, the precise displacement is obtained from phase shifts of spatial frequency spectra of two digital speckle images instead of digital correlation calculation. First, digital speckle images before and after displacement are windowed and fast Fourier transform is performed. Then, phase shifts of different spatial frequencies are linearly fitted in spectral space using the least square method, and a coarse displacement value is directly calculated according to the phase shift theorem of Fourier transform. By a window technique and iterative procedure, the influence of finite image size on the accuracy of the results is eliminated, and the accurate displacement is obtained finally. It is significant that the method obtains the subpixel-precision displacement without any interpolation operations. The test results show that the method has high computing efficiency, high precision, and good robustness to low image quality.

Upregulation of blood proBDNF and its receptors in major depression.

BACKGROUND: In recent decades, the role of brain-derived neurotrophic factor (BDNF) in depression has received intensive attention. However, the relationship between proBDNF and depression has not been clearly elucidated. METHODS: Forty drug-free women patients diagnosed with major depression and 50 healthy female controls were enrolled in our study. Peripheral blood was sampled from all the subjects. With the blood samples, we assessed the relationship between BDNF and major depression from following aspects: the levels of BDNF, proBDNF and their receptors in the sera and lymphocytes. The mRNA levels of these factors in lymphocytes were also examined. Furthermore, the correlations between each factor and the severity of major depression were tested. RESULTS: It was found that: (a) the protein and serum levels of proBDNF, sortilin and p75NTR were higher in major depressive patients than in healthy controls while mature BDNF and TrkB levels were lower; (b) the BDNF, TrkB, sortilin and p75NTR mRNA levels changed in line with their protein levels; (c) The levels of mature BDNF and TrkB had negative correlations with the major depression severity, and the levels of proBDNF, p75NTR and sortilin were positively correlated with the scores of HRSD-21; (d) the ratio of proBDNF and mBDNF was imbalanced in major depressive patients. CONCLUSION: The balance between the proBDNF/p75NTR/sortilin and mBDNF/TrkB signaling pathways appears dysregulated in major depression and both pathways should be considered as biomarkers for the major depression LIMITATIONS: More cases on both genders should be enrolled in our study. And further works on the mechanisms of how BDNF and its receptors are regulated in depression should also be carried out.

Stable and spacing-adjustable multiwavelength Raman fiber laser based on mixed-cascaded phosphosilicate fiber Raman linear cavity.

A novel multiwavelength Raman fiber laser based on the mixed-cascaded Stokes effects of phosphosilicate fiber is proposed and demonstrated experimentally. By using stimulated Raman scattering of both P(2)O(5) and SiO(2) along 1 km phosphosilicate fiber pumped with a 1064 nm double-clad fiber laser, the mixed-cascaded Raman linear cavity is formed by a pair of fiber Bragg gratings at 1239 nm, a polarization-maintaining fiber (PMF) Sagnac loop filter, and a conventional optical loop mirror. Up to 15-wavelength stable oscillations around 1320 nm are obtained with a wavelength spacing of 0.44 nm and power nonuniformity of less than 4 dB. By changing the length of the PMF in the Sagnac loop filter from 10 to 5.5 m, the wavelength spacing is adjustable from 0.44 to 0.8 nm. The extinction ratio of the laser is more than 30 dB. Excellent stability is also observed with a peak power fluctuation of less than 0.8 dB in 1 h.

Explicit solution for Raman fiber laser using Lambert W function.

In this paper, an approximate explicit solution for the first-order Raman fiber laser is obtained by using Lambert W function. Good agreement between the explicit solution and numerical simulation is demonstrated. Furthermore, the optimal design of Raman fiber laser is discussed using the proposed solution. The optimal values of fiber length, reflectivity of output fiber Bragg grating and power transfer efficiency are obtained under different pump power. There exists a certain tolerance of the optimal parameters, in which the output power decreases only slightly. The optimal fiber length and reflectivity of output FBG decrease with increasing pump power.